Duchenne Muscular Dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness. The disease is caused by an absence of dystrophin, a protein that helps keep muscle cells intact.
&nbsp;
DMD is caused by changes (mutations) in the DMD gene. The DMD gene codes for the protein dystrophin. Dystrophin is mainly made in skeletal and heart muscle cells, but a small amount is made in nerve cells (neurons) in specific parts of the brain. DMD is inherited in an X-linked recessive pattern and is passed on by the mother, referred to as a carrier; however, it may also occur in people who do not have a family history of DMD.&nbsp;
&nbsp;
Duchenne Muscular Dystrophy Epidemiological Segmentation
The Epidemiological Segmentation of Duchenne Muscular Dystrophy in 7MM from 2020 to 2034 is segmented as:-
<ul>
<li>Total Prevalent Population of Duchenne Muscular Dystrophy</li>
<li>Age-specific Prevalent Population of Duchenne Muscular Dystrophy&nbsp;</li>
<li>Ambulatory and Non-ambulatory Population of Duchenne Muscular Dystrophy</li>
<li>The mutation-specific prevalent population of Duchenne Muscular Dystrophy&nbsp;</li>
<li>Associated Comorbidities of&nbsp;Duchenne Muscular Dystrophy&nbsp;</li>
</ul>
&nbsp;
Duchenne Muscular Dystrophy Epidemiology (2020)
<ul>
<li>The total Duchenne Muscular Dystrophy prevalent population in 7MM was 30,688.</li>
<li>The total number of DMD prevalent cases in the United Kingdom was found to be 2,622.</li>
<li>The total number of Duchenne Muscular Dystrophy prevalent cases in the United States was found to be 16,765.</li>
<li>The total Duchenne Muscular Dystrophy prevalent cases in France were 2,101.</li>
<li>In Germany, the total number of DMD prevalent cases was observed to be 2,596.</li>
<li>The total number of Duchenne Muscular Dystrophy cases in Spain was estimated to be 1,478.</li>
</ul>
&nbsp;
<a style="color: #1155cc; background-color: transparent;" href="https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market" target="_blank" rel="noopener noreferrer">Duchenne Muscular Dystrophy Market</a>
The therapeutic market size of Duchenne Muscular Dystrophy in 7MM in 2020 was USD USD 745.4 million.
Duchenne Muscular Dystrophy Market Drivers
<ul>
<li>Robust Pipeline Activity</li>
<li>Upcoming Launches and Approval</li>
<li>Newborn Screening of DMD</li>
<li>Increasing Awareness Programs</li>
</ul>
&nbsp;
Duchenne Muscular Dystrophy Market Barriers
<ul>
<li>High Treatment Cost</li>
<li>Multidisciplinary Care</li>
<li>Lack of Treatment Options for non-ambulant DMD patients</li>
</ul>
Duchenne Muscular Dystrophy Emerging Drugs
The emerging drugs of the DMD market are:
<ul>
<li>PF-06939926</li>
<li>Vamorolone</li>
<li>Pizuglanstat (TAS-205)</li>
<li>Pamrevlumab (FG-3019)</li>
<li>SRP-9001</li>
<li>Allogeneic Cardiosphere-derived Cells (CAP-1002)</li>
<li>DS-5141b</li>
<li>Givinostat</li>
<li>ATL1102</li>
<li>SRP-5051</li>
<li>SGT-001</li>
</ul>
&nbsp;
And many more
&nbsp;
Duchenne Muscular Dystrophy Key Players
&nbsp;
The key players in the DMD market are:
&nbsp;
<ul>
<li>Pfizer</li>
<li>Santhera Pharmaceuticals/ReveraGen BioPharma</li>
<li>Taiho Pharmaceutical</li>
<li>FibroGen</li>
<li>Sarepta Therapeutics</li>
<li>Capricor</li>
<li>Daiichi Sankyo</li>
<li>Italfarmaco</li>
<li>Antisense Therapeutics</li>
<li>Sarepta Therapeutics</li>
<li>Solid Biosciences&nbsp;</li>
</ul>
&nbsp;
And many more

Duchenne Muscular Dystrophy Market

Duchenne Muscular Dystrophy Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.